Enterprise Value

190.3M

Cash

66.61M

Avg Qtr Burn

-17.54M

Short % of Float

6.15%

Insider Ownership

5.19%

Institutional Own.

52.13%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DEXTENZA® (dexamethasone ophthalmic insert) Details
Inflammation and pain following ophthalmic surgery

Approved

Quarterly sales

ReSure® Sealant Details
Intraoperative management of clear corneal incision

Approved

Quarterly sales

DEXTENZA® (dexamethasone ophthalmic insert) Details
Eye disease , Allergic conjunctivitis

Approved

Quarterly sales

OTX-TKI (axitinib intravitreal implant) Details
Wet age-related macular degeneration

Phase 3

Initiation

Phase 2

Data readout

Phase 2

Data readout

OTX-TIC (travoprost implant) Details
Primary open angle glaucoma , Ocular hypertension

Phase 2

Data readout

OTX-TKI (axitinib intravitreal implant) Details
Eye disease , Diabetic retinopathy

Phase 1

Data readout